Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 PET Scan Interpretation

Next Previous
Trial Profile

A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 PET Scan Interpretation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Flortaucipir-F-18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use; Registrational
  • Sponsors Avid Radiopharmaceuticals

Most Recent Events

  • 21 Jul 2020 According to an Eli Lilly and Company media release, data from this trial will be presented at the upcoming Alzheimers Association International Conference 2020 (AAIC 2020) which will be held virtually July 27-31, 2020
  • 28 May 2020 Results published in the U.S. Food and Drug Administration Media Release.
  • 28 May 2020 According to an U.S. Food and Drug Administration media release, it has approved Tauvid (flortaucipir F18) for intravenous injection under Priority Review. It is the first drug used to help image a distinctive characteristic of Alzheimer's disease in the brain called tau pathology. The safety and effectiveness of Tauvid imaging was evaluated in two clinical studies, Study 1 (NCT02516046) and Study 2 (NCT03901092).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top